NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-08-06 15:25இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
6-Year Forensic Audit initiated by SEBI for Nath Bio-Genes (FY21-FY26)
SEBI has appointed CNK & Associates LLP to conduct a forensic audit of Nath Bio-Genes (India) Limited, covering the period from FY 2020-21 to FY 2025-26. The audit will examine books of account and records based on specific matters identified by the regulator. With a market cap of ₹311 Cr and TTM revenue of ₹445 Cr, the company is currently trading at a low P/E of 7.5. The company has stated it is extending full cooperation to the auditors, though the specific triggers for the audit remain undisclosed.
உச்சம் நம்பிக்கை
என்ன மாறியதுSEBI has formally initiated a forensic audit of the company's financial records for the past six years.
ஏன் இது முக்கியம்A forensic audit by the regulator is a high-impact event that indicates concerns regarding financial reporting or governance, which could lead to significant penalties or operational restrictions if irregularities are found.
📅 குறுகிய காலம்Expect negative sentiment and potential price volatility in the coming weeks as the market reacts to the regulatory scrutiny.
📈 நீண்ட காலம்The long-term outlook is highly dependent on the audit findings; adverse results could permanently damage the company's valuation and credibility.
⚠ அபாய எச்சரிக்கைகள்
Regulatory Action
Governance Risk
Potential Financial Misstatement
👀 கவனிக்க வேண்டியவை
Investors should monitor for any subsequent disclosures regarding the findings of the forensic audit or any interim orders from SEBI; avoid reacting to speculation until findings are public.
15% Revenue Growth in Q1 FY27; Maize and Paddy Segments Drive Performance
Nath Bio-Genes reported a strong Q1 FY27 with revenue growing 15% YoY to ₹322.8 Cr, driven by significant gains in Maize and Paddy segments. EBITDA increased 17% to ₹35.1 Cr, maintaining an 11% margin despite a 31% surge in finance costs. The Maize segment was a standout performer with 59% value growth, while Paddy value grew 34% due to premium product contributions. This quarter is highly material, representing approximately 72.5% of the company's TTM revenue, highlighting the business's extreme seasonality.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company released its Q1 FY27 investor presentation, showing strong double-digit growth in revenue and EBITDA led by non-cotton segments.
ஏன் இது முக்கியம்Q1 is the most critical quarter for seed companies due to the Kharif sowing season; strong performance here is essential for meeting annual growth targets.
Q1 FY27 Revenue: ₹322.8 கோடிQ1 வருவாய் vs TTM வருவாய்: 72.5%Maize Value Growth: 59%EBITDA Growth (YoY): 17%Finance Cost Increase: 31%Net Debt (FY26): ₹51 கோடி
📅 குறுகிய காலம்The stock may see positive momentum as the company successfully navigated the peak season with strong volume and value growth in key crops.
📈 நீண்ட காலம்The shift toward high-margin segments like vegetables and premium hybrids is structurally positive for long-term margin expansion.
⚠ அபாய எச்சரிக்கைகள்
Extreme seasonality (heavy reliance on Q1)
Rising finance costs
Monsoon dependency for seed demand
👀 கவனிக்க வேண்டியவை
Watch for the company's ability to maintain margins in the off-peak quarters and monitor the impact of rising finance costs on net profitability.
Nath Bio-Genes Q1 FY27: Revenue Up 15.2% YoY to ₹322.84 Cr, PAT at ₹32.66 Cr
Nath Bio-Genes reported a strong start to FY27 with standalone revenue growing 15.2% YoY to ₹322.84 Cr for the June quarter. Net profit increased by 11.8% to ₹32.66 Cr, resulting in an EPS of ₹17.18 compared to ₹15.37 in the previous year. This quarter is seasonally the most significant for the company, contributing approximately 72.5% of its TTM revenue. Despite a rise in finance costs to ₹3.79 Cr, the company maintained steady operational margins.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has delivered double-digit growth in its most critical quarter (Q1), which typically accounts for the bulk of its annual earnings.
ஏன் இது முக்கியம்For a seed company, Q1 performance is the primary indicator of fiscal health; strong revenue realization here mitigates risks for the quieter remaining quarters.
📅 குறுகிய காலம்The stock may see positive sentiment as the results confirm growth in the peak sowing season.
📈 நீண்ட காலம்Long-term value depends on the company's ability to diversify revenue beyond the monsoon-dependent Q1 and scale its international joint venture in Uzbekistan.
⚠ அபாய எச்சரிக்கைகள்
High seasonal concentration of revenue
Rising finance costs
Susceptibility to monsoon patterns
👀 கவனிக்க வேண்டியவை
Watch for the management's commentary on monsoon impact and the progress of high-margin segments like vegetables and hybrid paddy, which are central to their 15% annual growth target.
Nath Bio-Genes FY26 Revenue Grows 19% to ₹4,316 Mn; Margins Contract to 12%
Nath Bio-Genes reported a strong 19% YoY revenue growth for FY26, reaching ₹4,316 million, driven by robust performance in Cotton (+28% value) and Maize (+78% value). However, profitability was under pressure as EBITDA remained flat at ₹525 million and Gross Margins compressed from 63% to 56%. A key highlight is the international expansion milestone, with Uzbekistan contributing ₹150 million to the top line for the first time. Despite the revenue jump, PAT (adjusted) declined by 8% YoY to ₹384 million.
முக்கிய அம்சங்கள்
Revenue increased by 19% YoY to ₹4,316 Mn, while EBITDA remained stagnant at ₹525 Mn.Cotton Bt volumes grew 22.35% with average realization rising to ₹293/kg.Gross Margin saw a significant contraction to 56% in FY26 from 63% in the previous year.International operations in Uzbekistan achieved a landmark ₹150 Mn revenue contribution.Net Debt increased significantly to ₹510 Mn from ₹235 Mn in FY25.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to recover margins and manage rising debt levels despite healthy top-line growth. The successful scale-up in Uzbekistan and growth in the Maize segment are positive long-term indicators to watch.
Nath Bio-Genes FY26 Revenue Up 19% to ₹431.6 Cr; Recommends ₹2 Dividend
Nath Bio-Genes (India) Limited reported a 19.1% growth in annual revenue for FY26, reaching ₹431.60 crore compared to ₹362.31 crore in FY25. Annual net profit saw a modest increase of 5.4% to ₹44.43 crore, despite a weaker fourth quarter where profit dipped to ₹3.79 crore. The Board has recommended a dividend of ₹2 per share (20% of face value). A significant management update includes the more than doubling of the Managing Director's remuneration to ₹1.44 crore per annum.
முக்கிய அம்சங்கள்
Annual Revenue from operations grew 19.1% YoY to ₹431.60 crore from ₹362.31 crore.Full-year Net Profit increased to ₹44.43 crore compared to ₹42.14 crore in the previous fiscal.Recommended a final dividend of ₹2.00 per equity share (20%) for FY 2025-26.Managing Director's annual remuneration increased by 118% from ₹66 lakhs to ₹1.44 crore.Inventory levels rose significantly to ₹444.60 crore from ₹330.71 crore YoY, indicating aggressive positioning for the next season.
👀 கவனிக்க வேண்டியவை
Investors should view the steady annual top-line growth and dividend payout positively, though the sharp hike in executive pay and rising inventory levels warrant close monitoring. The stock remains a play on the Indian agricultural cycle and seed demand.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Nath Bio-Genes Q3 Revenue Surges 79% to ₹660 Mn; PAT Up 67% YoY
Nath Bio-Genes reported a robust 79% YoY revenue growth in Q3FY26, reaching ₹660 million, primarily driven by a massive 142% value growth in the Maize segment. While Q3 PAT rose 67% to ₹45 million, EBITDA margins faced pressure, declining to 13% from 20% YoY. For 9MFY26, the company achieved a 23% revenue increase to ₹3,859 million, though PAT growth remained muted at 1%. The company is successfully diversifying its portfolio, with significant volume gains in Cotton (21%), Paddy (8%), and Vegetables (43%).
முக்கிய அம்சங்கள்
Q3FY26 Revenue increased by 79% YoY to ₹660 million; 9MFY26 Revenue up 23% to ₹3,859 million.Maize segment witnessed exceptional growth with volume up 94.77% and value up 141.98% YoY.Q3 EBITDA margin compressed to 13% from 20% YoY, while 9M EBITDA margin stood at 14%.Cotton segment remains the primary driver with 25.26% value growth in the first nine months.Vegetable seeds emerged as a fast-growing segment with a 52.08% increase in value during 9MFY26.
👀 கவனிக்க வேண்டியவை
Investors should cheer the strong top-line growth and diversification into high-value crops like Maize and Vegetables, but should closely monitor the impact of rising costs on EBITDA margins.
Nath Bio-Genes Q3 Standalone PAT Jumps 172% to ₹7.23 Cr; Consolidated Profit Declines
Nath Bio-Genes (India) Limited reported a robust standalone performance for Q3 FY26, with revenue growing 79% YoY to ₹65.96 crore and PAT surging 172% to ₹7.23 crore. However, the consolidated net profit for the quarter fell to ₹1.60 crore from ₹2.65 crore YoY, indicating significant losses or expenses within subsidiaries. For the nine-month period ended December 2025, consolidated revenue stood at ₹383.51 crore, up from ₹312.94 crore. Investors should note a qualified auditor's opinion regarding unassessed liabilities from new Labour Codes and the absence of actuarial valuations for employee benefits.
முக்கிய அம்சங்கள்
Standalone Revenue for Q3 FY26 increased 78.9% YoY to ₹65.96 crore from ₹36.87 crore.Standalone Net Profit for the quarter surged to ₹7.23 crore compared to ₹2.66 crore in the same period last year.Consolidated Net Profit for Q3 FY26 dropped to ₹1.60 crore, down from ₹2.65 crore in Q3 FY25.9M FY26 Consolidated Revenue grew 22.5% YoY to ₹383.51 crore from ₹312.94 crore.Auditors issued a qualified opinion due to the lack of financial impact assessment for new Labour Codes effective Nov 2025.
👀 கவனிக்க வேண்டியவை
Investors should investigate the widening gap between standalone and consolidated profits, as subsidiaries appear to be significantly impacting the bottom line. While standalone growth is strong, the auditor's qualification on labor code liabilities and missing actuarial valuations warrants caution regarding future provisions.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
